274 related articles for article (PubMed ID: 30278283)
41. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
[TBL] [Abstract][Full Text] [Related]
42. [Transcription factor RUNX1].
Markova EN; Petrova NV; Razin SV; Kantidze OL
Mol Biol (Mosk); 2012; 46(6):846-59. PubMed ID: 23350231
[TBL] [Abstract][Full Text] [Related]
43. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
[TBL] [Abstract][Full Text] [Related]
44. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
[TBL] [Abstract][Full Text] [Related]
45. RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study.
Shen L; Zhu J; Chen F; Lin W; Cai J; Zhong J; Zhong H
BMC Cancer; 2015 Dec; 15():970. PubMed ID: 26674644
[TBL] [Abstract][Full Text] [Related]
46. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
47. Prdm3 and Prdm16 cooperatively maintain hematopoiesis and clonogenic potential.
McGlynn KA; Sun R; Vonica A; Rudzinskas S; Zhang Y; Perkins AS
Exp Hematol; 2020 May; 85():20-32.e3. PubMed ID: 32437910
[TBL] [Abstract][Full Text] [Related]
48. Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
Tijchon E; van Emst L; Yuniati L; van Ingen Schenau D; Gerritsen M; van der Meer LT; Williams O; Hoogerbrugge PM; Scheijen B; van Leeuwen FN
Exp Hematol; 2018 Apr; 60():57-62.e3. PubMed ID: 29408281
[TBL] [Abstract][Full Text] [Related]
49. [Downregulation of activated leukemic oncogenes AML1-ETO and RUNX1(K83N) expression with RNA-interference].
Spirin PV; Baskaran F; Orlova NN; Rulina AV; Nikitenko NA; Chernolovskaia EL; Zenkova MA; Vlasov VV; Rubtsov PM; Chumakov PM; Stocking C; Prasolov VS
Mol Biol (Mosk); 2010; 44(5):876-88. PubMed ID: 21090242
[TBL] [Abstract][Full Text] [Related]
50. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
51. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
[TBL] [Abstract][Full Text] [Related]
52. Runx1/AML-1 ranks as a master regulator of adult hematopoiesis.
Ichikawa M; Asai T; Chiba S; Kurokawa M; Ogawa S
Cell Cycle; 2004 Jun; 3(6):722-4. PubMed ID: 15213471
[TBL] [Abstract][Full Text] [Related]
53. Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities.
Mehtonen J; Teppo S; Lahnalampi M; Kokko A; Kaukonen R; Oksa L; Bouvy-Liivrand M; Malyukova A; Mäkinen A; Laukkanen S; Mäkinen PI; Rounioja S; Ruusuvuori P; Sangfelt O; Lund R; Lönnberg T; Lohi O; Heinäniemi M
Genome Med; 2020 Nov; 12(1):99. PubMed ID: 33218352
[TBL] [Abstract][Full Text] [Related]
54. [Chromosomal rearrangements between 3q21 and 3q26 induce leukemogenesis by misdirecting both EVI1 and GATA2 genes].
Suzuki M
Rinsho Ketsueki; 2017; 58(7):806-812. PubMed ID: 28781278
[TBL] [Abstract][Full Text] [Related]
55. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
[TBL] [Abstract][Full Text] [Related]
56. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice.
Louz D; van den Broek M; Verbakel S; Vankan Y; van Lom K; Joosten M; Meijer D; Löwenberg B; Delwel R
Leukemia; 2000 Nov; 14(11):1876-84. PubMed ID: 11069022
[TBL] [Abstract][Full Text] [Related]
57. AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis.
Kurokawa M
Int J Hematol; 2006 Aug; 84(2):136-42. PubMed ID: 16926135
[TBL] [Abstract][Full Text] [Related]
58. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
[TBL] [Abstract][Full Text] [Related]
59. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice.
Tsuzuki S; Seto M; Greaves M; Enver T
Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8443-8. PubMed ID: 15155899
[TBL] [Abstract][Full Text] [Related]
60. Impairment of erythroid and megakaryocytic differentiation by a leukemia-associated and t(9;9)-derived fusion gene product, SET/TAF-Ibeta-CAN/Nup214.
Saito S; Nouno K; Shimizu R; Yamamoto M; Nagata K
J Cell Physiol; 2008 Feb; 214(2):322-33. PubMed ID: 17620317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
